Mind the Byte is a young and innovative company founded in 2011 and specialized on computational drug discovery. We offer solutions to improve and speed up pharmaceutical R&D and reduce its costs and risks.

We have demonstrated our capacity to attract public funding, capital risk and also small investors through two equity crowdfunding rounds. Integrity and accountability are the foundations of our efforts. We are committed to being open and transparent in our interactions with each other, our partners and investors.

Investors contact

Alfons Nonell-Canals:

Investor information

Preliminary details of the next round can be consulted.

Mind the Byte is a bioinformatics company specialized in Computational Drug Discovery. We offer solutions to improve and speed up the pharmaceutical R&D process and reduce its associated costs and risks. It is a young creative and entrepreneurial company, which is involved in R&D itself and constantly innovating. Currently, it is developing new applications using Machine Learning and Big Data technologies, which distances itself from the classical methods used in the field.

The company targets the biopharmaceutical industry, as well as research groups from the public and private sector. We have a scalable business model and offer our technology via Software as a Service (SaaS) platform, which comes with ad-hoc support services. In addition, Mind the Byte also offers scientific consultancy. We assist and help our clients during the entire process of drug development. Moreover, we are members of public-private consortiums that place Mind the Byte into the front line of technological development.

Updates for shareholders

January 19, 2018: Notice of call of the Shareholders meeting – 5th of February at 11am / Convocatoria de la Junta General de Socios – 5 de febrero a las 11h. (Download the PDF)